Fundraising Fox

Healium Intelliscan Corporation

Entrepreneur First '20

Bangalore, IN · Founded 2020 · 10 employees on LinkedIn · 2 known investors

Find your way into Healium Intelliscan Corporation

284 people in our graph share verified history with the Healium Intelliscan Corporation team — schools, employers, funds. One of them is your warm intro.

Toby Coppelunlockedknows Neeraj Kumar · together at Entrepreneur First (overlapped)
×5knows the team · via Entrepreneur First
×6knows the team · via MIT Sloan School of Management

Healium Digital Healthcare develops AI-powered point-of-care ultrasound technology that non-invasively detects chronic kidney disease (CKD) at early stages and identifies its root cause using digital biomarkers. Its tools generate patient-specific perfusion models and 3D kidney representations, supporting nephrologists and healthcare professionals in CKD screening, diagnosis, and progression monitoring.

Also known as Healium · Healium Intelliscan

Founders & leadership

Healium Intelliscan Corporation was founded in 2020 by Biju Jacob and Neeraj Kumar.

BJBiju Jacob
Biju JacobinCo-FounderBiju Jacob is a medical geneticist with experience in clinical research, regulatory affairs, and biomedical startup advisory. He has advised over 100 healthcare startups and worked across large organizations and early-stage ventures in medical research and innovation strategy.
NKNeeraj Kumar
Neeraj KumarinCo-Founder | Ultrasound AI for Early CKD DetectionNeeraj Kumar is cofounder of Healium Intelliscan Corporation, which develops AI-powered ultrasound technology to detect and stage chronic kidney disease. He has background in artificial intelligence, medical imaging, and product innovation.

Investors · 2

Company profile

researched Aug 2026

Healium Intelliscan Corporation is a medical technology company founded in 2020 that develops AI-enhanced point-of-care ultrasound (PoCUS) technology for the early detection and management of chronic kidney disease (CKD). Its ultrasound device applies AI to renal imaging in order to identify CKD non-invasively at early stages and to analyze underlying causes using digital biomarkers. The system produces patient-specific perfusion models and three-dimensional representations of the kidney intended to improve diagnostic clarity.

The platform provides real-time AI guidance and scan-quality evaluation so that healthcare professionals across skill levels can perform renal ultrasounds, and applies deep learning to ultrasound video for dynamic analysis of kidney function and flow. Additional described capabilities include predictive analytics for CKD progression, alerting on changes in CKD markers for continuous monitoring, encryption and privacy controls for patient data, scalable screening of high-risk populations, and patient education materials. The company states its device has been submitted for FDA 510(k) clearance and describes the clearance as pending.

Founding story

Sources state the company was established in 2020 by Dr. Biju Jacob and Neeraj Kumar, with the stated aim of improving global medical diagnostics through an AI-enhanced ultrasound device for precise CKD detection. No further founding details are provided.

Business model

Sources describe a medical device offering — an AI-powered ultrasound device for CKD detection and management sold or deployed to healthcare providers — but do not disclose pricing, contract structure, or commercial terms.

Traction

Limited disclosed traction. A directory listing reports 8 employees. The company website states it is backed by global investors, without naming them, and lists FDA 510(k) status as pending. A PrivCo profile contains no revenue, EBITDA, valuation, deal, or funding data.

Latest developments

The most recent disclosed development is the submission of the company's ultrasound device for FDA 510(k) clearance, with the status described as pending.

Full profile — market position, technology, go-to-market, geography, risks & controversies

Market position

Positioned in AI-driven medical imaging and nephrology diagnostics, focused on early CKD detection via point-of-care ultrasound. Sources provide no market share, revenue, or comparative ranking data; a PrivCo profile shows no reported financials, valuation, or funding.

Stated points of difference are AI-based root-cause/causality identification in addition to detection, clinically validated digital biomarkers, patient-specific perfusion modelling with 3D kidney reconstruction, and real-time operator guidance that is intended to let clinicians of varying skill levels capture high-quality renal scans.

Technology

AI-enhanced point-of-care ultrasound combining computer vision and deep learning. Described components include real-time scan support and quality evaluation for operators, enhanced image visualization of kidney structures, real-time processing of ultrasound video for dynamic flow and function analysis, clinically validated digital biomarkers, patient-specific perfusion modelling with 3D kidney reconstruction, causality/root-cause identification, and predictive algorithms for disease progression. Data handling is described as using encryption and privacy safeguards. A directory listing also notes use of common infrastructure such as Amazon AWS and Google/Gmail apps.

Go-to-market

Healthcare providers involved in kidney care, including nephrologists and healthcare professionals of varying ultrasound skill levels, and organizations screening high-risk patient populations for CKD.

Geography

Listings give a U.S. registered address at 8 The Green, Dover, Delaware 19901-3618; internal records place headquarters in Bangalore, India. The company frames its focus as the global CKD epidemic.

Risks & controversies

The device has not received FDA 510(k) clearance and remains pending, which is a regulatory dependency for U.S. commercialization. No revenue, funding, or financial data is available in the sources reviewed, and no controversies are reported.

Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
EmployeesJan 20258 people

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Timeline · 1

launches, deals, and filings
Jan 2025
FDA 510(k) submission pending for Healium ultrasound device

The company states its AI-powered renal ultrasound device has been submitted for FDA 510(k) clearance, with clearance status listed as pending.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Research sources · 5

primary sources listed

5 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Healium Intelliscan Corporation do?
Medtech company building AI-enhanced point-of-care renal ultrasound for early chronic kidney disease detection.
Who founded Healium Intelliscan Corporation?
Healium Intelliscan Corporation was founded by Biju Jacob, Neeraj Kumar in 2020.
Who are Healium Intelliscan Corporation's investors?
Healium Intelliscan Corporation's investors include Entrepreneur First, Powerhouse Ventures.
Where is Healium Intelliscan Corporation headquartered?
Healium Intelliscan Corporation is headquartered in Bangalore, IN.